NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis $2.52 +0.32 (+14.55%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends About Avenue Therapeutics Stock (NASDAQ:ATXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avenue Therapeutics alerts:Sign Up Key Stats Today's Range$2.20▼$2.6350-Day Range$1.98▼$3.0252-Week Range$1.70▼$29.25Volume223,640 shsAverage Volume61,751 shsMarket Capitalization$2.37 millionP/E Ratio0.10Dividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Avenue Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreATXI MarketRank™: Avenue Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Avenue Therapeutics.Read more about Avenue Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is 0.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.78.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is 0.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.01.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Avenue Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.01% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 13.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted2.01% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 13.02%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment-0.03 News SentimentAvenue Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avenue Therapeutics this week, compared to 7 articles on an average week.Search Interest1 people have searched for ATXI on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Avenue Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions.Read more about Avenue Therapeutics' insider trading history. Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXI Stock News HeadlinesCollege Avenue park-and-ride lots closed following increased police callsOctober 29 at 1:42 AM | yahoo.comDemolition begins for historic Auburn Avenue TheaterOctober 22, 2024 | msn.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 29, 2024 | Paradigm Press (Ad)Shooter sentenced in Wellington Avenue murderOctober 11, 2024 | yahoo.comBirmingham PD: Homicide investigation underway on 4th Avenue NOctober 11, 2024 | msn.comEastbound lanes on I-10 near Lenox Avenue reopened following crash with injuriesOctober 11, 2024 | msn.comPortions of Crane Avenue to reopen amid reconstruction projectOctober 11, 2024 | msn.comNormal Avenue closure for utility workOctober 9, 2024 | yahoo.comSee More Headlines ATXI Stock Analysis - Frequently Asked Questions How have ATXI shares performed this year? Avenue Therapeutics' stock was trading at $12.0750 on January 1st, 2024. Since then, ATXI shares have decreased by 79.1% and is now trading at $2.52. View the best growth stocks for 2024 here. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) released its earnings results on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $5.38. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split before market open on Friday, April 26th 2024. The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. Who are Avenue Therapeutics' major shareholders? Top institutional investors of Avenue Therapeutics include Moss Adams Wealth Advisors LLC (1.17%). Insiders that own company stock include Fortress Biotech, Inc, Lindsay A Md Rosenwald and Invagen Pharmaceuticals, Inc. View institutional ownership trends. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), General Electric (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/09/2024Today10/28/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXI CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Most Recent Fiscal Year)($7.88) Trailing P/E Ratio0.10 Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,263.54% Return on Assets-220.32% Debt Debt-to-Equity RatioN/A Current Ratio4.30 Quick Ratio4.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book1.31Miscellaneous Outstanding Shares941,000Free Float1,405,000Market Cap$2.37 million OptionableNot Optionable Beta-0.17 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ATXI) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.